Showing results (561-570 of 594) with videos related to

Sort By:
Pageof 60
Annals of Hepatology|August 14, 2022
Randomised controlled trial: effect of metformin add-on therapy on functional cure in entecavir-treated patients with chronic hepatitis BWei Zhang, Yuan-Yuan Li, Qing-Hua Shang, et al.
Plos One|June 5, 2012
Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infantsFeng-Cai Zhu, Zheng-Lun Liang, Fan-Yue Meng, et al.
The Lancet. Infectious Diseases|May 22, 2023
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trialJun-Dong Wu, Jing-Xin Li, Jian Liu, et al.
Chinese Medical Journal|April 30, 2021
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trialsHong-Xing Pan, Jian-Kai Liu, Bao-Ying Huang, et al.
Expert Review of Vaccines|September 1, 2022
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and aboveZhuo-Pei Li, Yun-Feng Shi, Li-Hua Hou, et al.
The Lancet. Respiratory Medicine|May 23, 2022
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJing-Xin Li, Shi-Po Wu, Xi-Ling Guo, et al.
Lancet (London, England)|March 31, 2015
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialFeng-Cai Zhu, Li-Hua Hou, Jing-Xin Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 7, 2025
Long-chain unsaturated free fatty acids control gut motility via nitrergic ganglia of the enteric nervous systemJun-Hao Zhang, Zhi-Hui Jiang, Ji Xuan, et al.
Plos One|May 15, 2013
Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesLi-Xin Wang, Zhen-Yang Mei, Ji-Hao Zhou, et al.
Lancet (London, England)|December 27, 2016
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Alie H Wurie, Li-Hua Hou, et al.
Pageof 60